Dual-particle cancer therapy combines cancer drug with TRAIL for a one-two punch


Researchers from Cornell University have developed a combination therapy to treat cancers such as prostate and colon. The nanoparticle delivery platform uses a simple nanoparticle design but two separate vehicles.

The two independent particles include one that encapsulates the cancer drug piperlongumine (PL) and a second that has the protein TRAIL on its surface. TRAIL induces the process of cell death called apoptosis.

The scientists first administered the PL to sensitize the cancer cells. And then the TRAIL, chemically conjugated to the surface of liposomes, gave the tumor a final blow. They found in mice that apoptotic rates were higher with the dual therapy than with the cancer drug alone.

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

They published their findings in the journal Technology.

"We have found that liposomal TRAIL shows great promise for the destruction of tumor cells in the bloodstream, lymphatic system, and also in solid tumors," senior author Michael King said in a statement, along with members from his team.

- here's the release

Suggested Articles

Ad Environment Matters for Message Receptivity

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

As Halozyme's drug delivery platform pulls in profits from J&J and Roche partnerships, the company has signed its tenth global Enhanze deal.